Photocure ASA Reports Impressive Q3 2025 Results with Strong Revenue Growth Photocure ASA has announced strong financial results for Q3 2025, showcasing significant revenue growth and strategic partnerships aimed at enhancing bladder cancer detection.

Photocure ASA Reports Impressive Q3 2025 Results with Strong Revenue Growth #Norway #Oslo #Photocure_ASA #Hexvix #Cysview

Photocure ASA Reports Impressive Q3 2025 Financial Results with Continued Growth Outlook Photocure ASA highlights strong financial performance in Q3 2025, with increasing revenues and the advent of strategic partnerships for growth. Looking ahead, they anticipate sustained growth in bladder cancer diagnostics.

Photocure ASA Reports Impressive Q3 2025 Financial Results with Continued Growth Outlook #Norway #Oslo #Photocure_ASA #Hexvix #Cysview

Photocure ASA Reports Strong Growth for Q4 2024 Results Photocure ASA shares impressive fourth quarter results with record revenues and product growth for Hexvix and Cysview, projecting continued success for 2025.

Photocure ASA Reports Strong Growth for Q4 2024 Results #Norway #Oslo #Photocure_ASA #Hexvix #Cysview

Photocure ASA Reports Robust Financial Performance in Q4 2024 Photocure ASA showcases impressive revenue growth in Q4 2024, driven by rising sales of Hexvix®/Cysview®. The company anticipates continued momentum through 2025.

Photocure ASA Reports Robust Financial Performance in Q4 2024 #Norway #Oslo #Photocure_ASA #Hexvix #Cysview